Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion type Assertion NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_head.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion evidence source_evidence_literature NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion SIO_000772 16341239 NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion wasDerivedFrom befree-2016 NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion wasGeneratedBy ECO_0000203 NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.